pSivida Corp., (NASDAQ: PSDV) (ASX: PVA) headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, the U.K. Spain, and Italy. ILUVIEN for DME has recently been approved in the US. pSivida plans to institute pivotal Phase III clinical trials for the treatment of posterior uveitis with the same micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida's two FDA-approved products, Retisert® and Vitrasert®, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

Company Growth (employees)
Watertown, US
Size (employees)
20 (est)-23%
pSivida is headquartered in Watertown, US

pSivida Office Locations

pSivida has offices in Watertown and Worcestershire
Watertown, US (HQ)
B300 480 Pleasant St
Worcestershire, GB
Geraldine Rd Aspen House

pSivida Metrics

pSivida Financial Metrics

pSivida's revenue was reported to be $1.6 m in FY, 2016 which is a 94% decrease from the previous period.

Revenue (FY, 2016)

$1.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

($21.5 m)

EBIT (FY, 2016)

($21.8 m)

Market capitalization (22-May-2017)

$86.8 m

Closing share price (22-May-2017)


Cash (30-Jun-2016)

$15.3 m
pSivida's current market capitalization is $86.8 m.
FY, 2014FY, 2015FY, 2016


$3.5 m$26.6 m$1.6 m

Revenue growth, %


R&D expense

$9.6 m$12.1 m$14.4 m

General and administrative expense

$7.5 m$8.1 m$9 m

Operating expense total

$17 m$20.1 m$23.4 m


($13.5 m)$6.4 m($21.8 m)

EBIT margin, %


Interest income

$72 k

Pre tax profit

($13.5 m)$6.4 m($21.7 m)

Income tax expense

$130 k($96 k)$155 k

Net Income

($13.4 m)$6.3 m($21.5 m)
FY, 2014FY, 2015FY, 2016


$15.3 m$19.1 m$15.3 m

Accounts Receivable

$11.9 m


$547 k$681 k$483 k

Current Assets

$19.3 m$29.8 m$30 m


$297 k$338 k$290 k

Total Assets

$22.7 m$32.4 m$31.6 m

Accounts Payable

$464 k$744 k$1.4 m

Current Liabilities

$2.1 m$3.3 m$5.1 m

Additional Paid-in Capital

$290.9 m$293.1 m$312.2 m

Retained Earnings

($277 m)($270.7 m)($292.2 m)

Total Equity

$14.9 m$23.4 m$20.9 m

Financial Leverage

1.5 x1.4 x1.5 x
FY, 2014FY, 2015FY, 2016

Net Income

($13.4 m)$6.3 m($21.5 m)

Depreciation and Amortization

$139 k$112 k$152 k


$1.1 m($136 k)$187 k

Accounts Payable

($213 k)$292 k$626 k

Cash From Operating Activities

$8.4 m$3.8 m($3.8 m)

Purchases of PP&E

($248 k)($161 k)($113 k)

Cash From Investing Activities

$66 k($6.7 m)($4.5 m)

Cash From Financing Activities

$19 m$235 k$17 m

Income Taxes Paid

$263 k$4 k
Y, 2016


$62.3 k

Financial Leverage

1.5 x

pSivida Market Value History

pSivida Online Presence

pSivida News

pSivida Company Life

You may also be interested in